Correction of glycogenosis type 2 by muscle-specific lentiviral vector

In Vitro Cellular and Developmental Biology - Animal

Volumn 44, Issue 10, 2009, Pages 397-406

  Richard, Emmanuel ^a,b   Douillard Guilloux, Gaëlle ^a   Batista, Lionel ^a   Caillaud, Catherine ^a  

^a INSTITUT COCHIN   (France)

^b INSERM   (France)

Author keywords

Acid maltase; Glycogen storage disease; Lentiviral vector; Lysosomal enzyme; Pompe disease

Indexed keywords

GLUCAN 1,4 ALPHA GLUCOSIDASE; GLUCOSIDASE; GLYCOGEN; LENTIVIRUS VECTOR; MANNOSE 6 PHOSPHATE; PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME RELEASE; FIBROBLAST; GENE TRANSFER; GLYCOGEN METABOLISM; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; MOUSE; MUSCLE CELL; MYOBLAST; NONHUMAN; PHENOTYPE; PROMOTER REGION; PROTEIN ANALYSIS; SATELLITE CELL;

ALPHA-GLUCOSIDASES; ANIMALS; CELL LINE; FIBROBLASTS; GENE THERAPY; GENETIC VECTORS; GLYCOGEN; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; LENTIVIRUS; LYSOSOMES; MICE; MUSCLES; MYOBLASTS; ORGAN SPECIFICITY; RECEPTOR, IGF TYPE 2; TRANSDUCTION, GENETIC; VIRUS INACTIVATION;

MURINAE;

EID: 65149084155     PISSN: 10712690     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11626-008-9138-5     Document Type: Article

References (42)

1. A. G. Bijvoet E. H. van de Kamp M. A. Kroos J. H. Ding B. Z. Yang P. Visser C. E. Bakker M. P. Verbeet B. A. Oostra A. J. Reuser A. T. Van der Ploeg 1998 Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease Hum. Mol. Genet 7 53 62 (Pubitemid 28040737)
2. M. Cavazzana-Calvo A. Fischer 2007 Gene therapy for severe combined immunodeficiency: are we there yet? J. Clin. Invest. 117 1456 1465 (Pubitemid 46871328)
3. A. H. Chang M. Sadelain 2007 The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the LTR, and the promise of lineage-restricted vectors Mol. Ther. 15 445 456 (Pubitemid 46306587)
4. Coffin, J. M.; Hugues, S. H.; Varmus, H. E. Retroviruses. Cold Spring Harbour Laboratory Press, Cold Spring Harbor, New York;1997.
5. G. G. D'Ancona J. Wurm C. M. Croce 1979 Genetics of type II glycogenosis: assignment of the human gene for acid alpha-glucosidase to chromosome 17 Proc. Natl. Acad. Sci. USA 76 4526 4529 (Pubitemid 9256513)
6. R. Draghia-Akli K. M. Ellis L. A. Hill P. B. Malone M. L. Fiorotto 2003 High-efficiency growth hormone-releasing hormone plasmid vector administration into skeletal muscle mediated by electroporation in pigs FASEB J 17 526 528
7. T. J. Fraites Jr. M. R. R. Schleissing A. Shanely G. A. Walter D. A. Coutier I. Zolotukhin D. F. Pauly N. Raben P. H. Plotz S. K. Powers P. D. Kessler B. J. Byrne 2002 Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors Mol. Ther 5 571 578 (Pubitemid 34546087)
8. L. M. Franco B. Sun X. Yang A. Bird H. Zhang A. Schneider T. Brown S. P. Young T. M. Clay A. Amalfitano Y. T. Chen D. D. Koeberl 2005 Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II Mol. Ther 12 876 884 (Pubitemid 41614483)
9. S. Halene L. Wang R. M. Cooper D. C. Bockstoce P. B. Robbins D. B. Khon 1999 Improved expression in hematopoietic and lymphoid cells in mice after transplantation of bone marrow transduced with a modified retroviral vector Blood 94 3349 3357 (Pubitemid 29536128)
10. Hirschhorn, R.; Reuser, A. J. J. Glycogen storage disease type II: acid α-glucosidase (acid maltase) deficiency. In: Scriver, C. R.; Baudet, A. L.; Sly W. S.; Valle, D. (eds) The metabolic and molecular bases of inherited diseases. McGraw-Hill, New York, pp 3389-3420; 2001.
11. T. Kafri U. Blomer D. A. Peterson F. H. Gage I. M. Verma 1997 Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors Nat. Genet 17 314 317 (Pubitemid 27475995)
12. L. Klinge V. Straub U. Neudorf J. Schaper T. Bosbach K. Gorlinger M. Wallot S. Richards T. Voit 2005 Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial Neuromuscul. Disord. 15 24 31 (Pubitemid 41556629)
13. L. W. Katzin A. A. Amato 2008 Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy J. Clin. Neuromuscul. Dis 9 421 431
14. P. S. Kishnani D. Corzo M. Nicolino B. Byrne H. Mandel W. L. Hwu N. Leslie J. Levine C. Spencer M. McDonald J. Li J. Dumontier M. Halberthal Y. H. Chien R. Hopkin S. Vijayaraghavan D. Gruskin D. Bartholomew A. van der Ploeg J. P. Clancy R. Parini G. Morin M. Beck G. S. De la Gastine M. Jokic B. Thurberg S. Richards D. Bali M. Davison M. A. Worden Y. T. Chen J. E. Wraith 2007 Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease Neurology 9 99 109 (Pubitemid 46071892)
15. E. Li M. Eastman R. J. Schwartz R. Draghia-Akli 1999 Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences Nat. Biotechnol 17 241 245 (Pubitemid 29122631)
16. C. Liu A. B. Bahnson J. T. Dunigan S. C. Watkins J. A. Barranger 1998 Long-term expression and secretion of human glucocerebrosidase by primary murine and human myoblasts and differentiated myotubes J. Mol. Med. 76 773 781 (Pubitemid 28475172)
17. Y. L. Liu F. Mingozzi S. M. Rodriguez-Colon S. Joseph E. Dobrzynski T. Suzuki K. A. High R. W. Herzog 2004 Therapeutic levels of factor IX expression using a muscle-specific promoter and adeno-associated virus serotype 1 vector Hum. Gene Ther 15 783 792 (Pubitemid 39095250)
18. E. Martin-Touaux J. P. Puech D. Chateau C. Emiliani E. J. Kremer N. Raben B. Tancini A. Orlacchio A. Kahn L. Poenaru 2002 Muscle as a putative producer of acid alpha-glucosidase for glycogenosis type II gene therapy. Hum. Mol. Genet 11 1637 1645
19. F. Martiniuk M. Bodkin S. Tzall R. Hirschhorn 1991 Isolation and partial characterization of the structural gene for human acid alpha glucosidase DNA Cell Biol 10 283 292
20. F. Moreau-Gaudry P. Xia G. Jiang N. P. Perelman G. Bauer J. Ellis K. H. Surinya F. Mavilio C. K. Chen P. Malik 2001 High-level erythroid-specific gene expression in primary human and murine hematopoietic cells with self-inactivating lentiviral vectors Blood 98 2664 2672
21. M. G. Ott R. Seger S. Stein U. Siler D. Hoelzer M. Grez 2007 Advances in the treatment of chronic granulomatous disease by gene therapy Curr. Gene Ther. 7 155 161 (Pubitemid 46902198)
22. Pinset, C.; Montarras, D. Cell biology: a laboratory handbook. Academic, San Diego1994.
23. S. P. Queneville P. Chapdelaine D. Skuk M. Paradis M. Goulet J. Rousseau X. Xiao L. Garcia J. P. Tremblay 2007 Autologous transplantation of muscle precursor cells modified with a lentivirus for muscular dystrophy: human cells and primate models. Mol. Ther. 15 431 438 (Pubitemid 46111895)
24. N. Raben M. Danon A. L. Gilbert S. Dwivedi B. Collins B. L. Thurberg R. J. Mattaliano K. Nagaraju P. H. Plotz 2003 Enzyme replacement therapy in the mouse model of Pompe disease Mol. Genet Metab. 80 159 169 (Pubitemid 37272242)
25. N. Raben K. Nagaraju E. Lee P. Kessler B. Byrne L. Lee M. Lamarca C. King J. Ward B. Sauer P. Plotz 1998 Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J. Biol. Chem. 273 19086 19092 (Pubitemid 28366303)
26. E. Richard E. Robert M. Cario-Andre C. Ged F. Geronimi S. L. Gerson H. de Verneuil F. Moreau-Gaudry 2004 Hematopoietic stem cell gene therapy of murine protoporphyria by methylguanine-DNA-methyltransferase-mediated in vivo drug selection Gene Ther. 11 1638 1647 (Pubitemid 39530100)
27. B. C. Schnepp K. R. Clark D. L. Klemanski C. A. Pacak P. R. Johnson 2003 Genetic fate of recombinant adeno-associated virus vector genomes in muscle J. Virol. 77 3495 3504 (Pubitemid 36297269)
28. B. Sun A. Bird S. P. Young P. S. Kishnani Y. T. Chen D. D. Koeberl 2007 Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. Am. J. Hum. Genet. 81 1042 1049 (Pubitemid 47580255)
29. B. Sun H. Zhang D. K. Benjamin Jr T. Brown A. Bird S. P. Young A. McVie-Wylie Y. T. Chen D. D. Koeberl 2006 Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II. Mol. Ther. 14 822 830
30. B. Sun H. Zang L. M. Franco T. Brown A. Bird A. Schneider D. D. Koeberl 2005 Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter Mol. Ther. 11 889 898 (Pubitemid 40724107)
31. B. Sun H. Zhang L. M. Franco S. P. Young A. Schneider A. Bird A. Amalfitano Y. T. Chen D. D. Koeberl 2005 Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. Mol. Ther. 11 57 65 (Pubitemid 40011999)
32. K. Umapathysivam J. J. Hopwood P. J. Meikle 2005 Correlation of acid alpha-glucosidase and glycogen content in skin fibroblasts with age of onset in Pompe disease Clin. Chim. Acta 361 191 198 (Pubitemid 41382623)
33. A. T. Van der Ploeg M. Kroos J. M. van Dongen W. J. Visser P. A. Bolhuis M. C. Loonen A. J. Reuser 1987 Breakdown of lysosomal glycogen in cultured fibroblasts from glycogenosis type II patients after uptake of acid alpha-glucosidase. J. Neurol. Sci. 79 327 336 (Pubitemid 17081184)
34. A. T. Van der Ploeg L. P. Winkel J. M. Van den Hout J. H. Kamphoven J. A. Disseldorp M. Remmerswaal W. F. Arts M. C. Loonen A. G. Vulto P. A. Van Doorn G. de Jong W. Hop G. P. Smit S. K. Shapira M. A. Boer O. P. Van Diggelen A. J. Reuser 2004 Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann. Neurol. 55 495 502 (Pubitemid 38391966)
35. N. Vincent-Lacaze R. O. Snyder R. Gluzman D. Bohl C. Lagarde O. Danos 1999 Structure of adeno-associated virus vector DNA following transduction of the skeletal muscle. J. Virol 73 1949 1955 (Pubitemid 29098096)
36. H. A. Wisselaar M. A. Kroos M. M. Hermans J. van Beeumen A. J. Reuser 1993 Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation J. Biol. Chem. 268 2223 2231 (Pubitemid 23033637)
37. F. Xu E. Ding F. Migone D. Serra A. Schneider Y. T. Chen A. Amalfitano 2005 Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA. J. Gene Med. 7 171 178 (Pubitemid 40348021)
38. A. Zaldumbide R. C. Hoeben 2008 How not to be seen: immune-evasion strategies in gene therapy Gene Ther. 15 239 246
39. J. Z. Zaretzky F. Candotti C. Boerkoel E. M. Adams J. W. Yewdell R. M. Blaese P. H. Plotz 1997 Retroviral transfer of acid alpha-glucosidase cDNA to enzyme-deficient myoblasts results in phenotypic spread of the genotypic correction by both secretion and fusion Hum. Gene Ther. 8 1555 1563 (Pubitemid 27455291)
40. R. J. Ziegler S. D. Bercury J. Fidler M. A. Zhao J. Foley T. V. Taksir S. Ryan B. L. Hodges R. K. Scheule L. S. Shihabuddin S. H. Cheng 2008 Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice Hum. Gene Ther. 19 609 721
41. R. Zufferey J. E. Donello D. Trono T. J. Hope 1999 Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J. Virol. 73 2886 2892 (Pubitemid 29135675)
42. R. Zufferey T. Dull R. J. Mandel A. Bukovsky D. Quiroz L. Naldini D. Trono 1998 Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery J. Virol. 72 9873 9880 (Pubitemid 28520853)